Source:http://linkedlifedata.com/resource/pubmed/id/21198725
Switch to
| Predicate | Object |
|---|---|
| rdf:type | |
| lifeskim:mentions | |
| pubmed:issue |
1
|
| pubmed:dateCreated |
2011-1-4
|
| pubmed:abstractText |
WHAT IS KNOWN AND OBJECTIVE: Telmisartan, an angiotensin II type 1 receptor blocker (ARB), acts as a partial agonist for peroxisome proliferator-activated receptor-?, and thus improves abnormalities of glucose metabolism and hypertriglyceridaemia in addition to its documented blood pressure-lowering effects. Recently, it has been demonstrated that telmisartan also lowers the levels of total cholesterol and low-density lipoprotein (LDL) cholesterol levels. This study was designed to investigate the mechanism of cholesterol reduction. METHODS: We measured serum levels of cholestanol, a cholesterol absorption marker, and lathosterol, a cholesterol synthesis marker, in 20 patients with both hypercholesterolaemia and hypertension. Ten patients were treated with telmisartan and the remaining 10 with fluvastatin. RESULTS: After 3 months of treatment, total and LDL cholesterol levels decreased in the telmisartan group (P<0.01 for both total and LDL cholesterol levels) and the fluvastatin group (P<0.001 for both total and LDL cholesterol levels). The change in cholestanol level after 3 months of treatment was positively correlated with the levels of total (R=0.72, P<0.05) and LDL cholesterol (R=0.81, P<0.01) in the telmisartan group. The change in lathosterol level was positively correlated with the levels of total (R=0.88, P=0.001) and LDL cholesterol (R=0.89, P=0.001) in the fluvastatin group. WHAT IS NEW AND CONCLUSIONS: Our results suggest that the cholesterol-lowering effect of telmisartan might be caused by inhibition of cholesterol absorption, whereas that of statins is by inhibition of cholesterol synthesis. If confirmed, co-treatment with the two agents may be useful for synergistically lowering cholesterol in hypertensive patients.
|
| pubmed:language |
eng
|
| pubmed:journal | |
| pubmed:citationSubset |
IM
|
| pubmed:chemical |
http://linkedlifedata.com/resource/pubmed/chemical/Angiotensin II Type 1 Receptor...,
http://linkedlifedata.com/resource/pubmed/chemical/Anticholesteremic Agents,
http://linkedlifedata.com/resource/pubmed/chemical/Benzimidazoles,
http://linkedlifedata.com/resource/pubmed/chemical/Benzoates,
http://linkedlifedata.com/resource/pubmed/chemical/Biological Markers,
http://linkedlifedata.com/resource/pubmed/chemical/Cholestanol,
http://linkedlifedata.com/resource/pubmed/chemical/Cholesterol,
http://linkedlifedata.com/resource/pubmed/chemical/Cholesterol, LDL,
http://linkedlifedata.com/resource/pubmed/chemical/Fatty Acids, Monounsaturated,
http://linkedlifedata.com/resource/pubmed/chemical/Gastrointestinal Agents,
http://linkedlifedata.com/resource/pubmed/chemical/Indoles,
http://linkedlifedata.com/resource/pubmed/chemical/PPAR gamma,
http://linkedlifedata.com/resource/pubmed/chemical/fluvastatin,
http://linkedlifedata.com/resource/pubmed/chemical/lathosterol,
http://linkedlifedata.com/resource/pubmed/chemical/telmisartan
|
| pubmed:status |
MEDLINE
|
| pubmed:month |
Feb
|
| pubmed:issn |
1365-2710
|
| pubmed:author | |
| pubmed:copyrightInfo |
© 2010 Blackwell Publishing Ltd.
|
| pubmed:issnType |
Electronic
|
| pubmed:volume |
36
|
| pubmed:owner |
NLM
|
| pubmed:authorsComplete |
Y
|
| pubmed:pagination |
103-10
|
| pubmed:meshHeading |
pubmed-meshheading:21198725-Aged,
pubmed-meshheading:21198725-Aged, 80 and over,
pubmed-meshheading:21198725-Angiotensin II Type 1 Receptor Blockers,
pubmed-meshheading:21198725-Anticholesteremic Agents,
pubmed-meshheading:21198725-Benzimidazoles,
pubmed-meshheading:21198725-Benzoates,
pubmed-meshheading:21198725-Biological Markers,
pubmed-meshheading:21198725-Cholestanol,
pubmed-meshheading:21198725-Cholesterol,
pubmed-meshheading:21198725-Cholesterol, LDL,
pubmed-meshheading:21198725-Fatty Acids, Monounsaturated,
pubmed-meshheading:21198725-Female,
pubmed-meshheading:21198725-Gastrointestinal Agents,
pubmed-meshheading:21198725-Humans,
pubmed-meshheading:21198725-Hypercholesterolemia,
pubmed-meshheading:21198725-Hypertension,
pubmed-meshheading:21198725-Indoles,
pubmed-meshheading:21198725-Intestinal Absorption,
pubmed-meshheading:21198725-Male,
pubmed-meshheading:21198725-Middle Aged,
pubmed-meshheading:21198725-PPAR gamma
|
| pubmed:year |
2011
|
| pubmed:articleTitle |
Inhibition of intestinal cholesterol absorption might explain cholesterol-lowering effect of telmisartan.
|
| pubmed:affiliation |
Department of Cardiovascular Medicine, Dokkyo Medical University, Mibu, Tochigi, Japan. inouet@dokkyomed.ac.jp
|
| pubmed:publicationType |
Journal Article,
Comparative Study,
Controlled Clinical Trial
|